PR

MEZOO, connecting health through technology
Sharing MEZOO’s technology and vision.
External
2026.03.20
Closing the 'monitoring gap' in hospital settings using Hicardi

Digital healthcare technology aimed at eliminating blind spots in hospital patient monitoring is garnering significant attention. MEZOO, a specialized medical device company, is drawing interest from the medical community by proposing a comprehensive, continuous monitoring system through its mobile remote patient monitoring platform, 'HiCardi.'


MEZOO will participate in KIMES 2026 (Korea International Medical & Hospital Equipment Show) to showcase its patient monitoring solutions based on aRPM (Ambulatory Remote Patient Monitoring) technology.

At their booth, the company will introduce clinical application cases, explain the technical architecture, and host product briefings and one-on-one consultations for medical professionals.


Founded by experts with Ph.D.s in Biomedical Engineering from Yonsei University, MEZOO has been developing digital healthcare solutions based on biomedical telemetry technology to continuously monitor patient vital signs both inside and outside the hospital.

Currently, HiCardi is supplied to approximately 53% of tertiary general hospitals in South Korea, establishing itself as a next-generation patient monitoring platform.


◇ aRPM: A Mobile Remote Patient Monitoring Platform

Traditional hospital patient monitoring systems are primarily centered around operating rooms, Intensive Care Units (ICUs), and specific special wards.

While fixed, wired monitoring equipment is designed for stable surveillance at the bedside, its high cost and the burden of building central control infrastructure often limit its use to critically ill patients.


Consequently, in general wards—which account for about 80% to 90% of all hospital beds—it has been difficult to maintain continuous monitoring of vital signs. "Monitoring blind spots" persist within hospitals, particularly when patients move between wards or during transport for tests and procedures, leading to intermittent gaps in data.


Recognizing these unmet medical needs, MEZOO developed HiCardi, an ambulatory Remote Patient Monitoring (aRPM) platform.


HiCardi is not intended to replace existing ICU-centric equipment. Instead, it is a platform designed to expand existing systems—which are currently bedside-oriented—to a ward-wide and, eventually, a hospital-wide scale.

Its goal is to create an integrated monitoring environment for the entire hospital by seamlessly connecting patients in general wards, those in transit, and those in isolation units.


Source: Bokuen News (http://www.bokuennews.com/news/article.html?no=275169)

 

적용 법률 및 규정
의료기기

하이카디® 시스템은 인허가에 따라 신생아, 소아, 청소년, 18세 이상 환자의 ECG 데이터를 측정하여 부정맥을 진단하는 의료기기로서 의료전문가가 사용하도록 설계되었습니다. 한국 KFDA로부터 의료기기 2등급 인증을 받았습니다. 유럽의료기기 지침(2007/47/EC에 따라 개정된 MDD 93/42/EEC)에 따라 준수된 Class IIb (CE2265). 의료기기 제품으로 CE 승인되었습니다. 미국 FDA는 Class II 510K로 승인 완료 예정입니다.

경고

본 자료는 의료 전문가에게만 배포되며 관련 사진과 함께 제공되는 자료와 관련하여 그 어떤 법적인 책임을 갖지 않습니다. 사용 전 사용 지침서를 주의 깊게 읽으십시오.